Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

EMBER-3 : EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Breast<br/>CancersCancer LocationBreast
Cancers

Systemic therapy | BreastBreast

Trial Overview Read MoreRead more

This phase III study is measuring how well a new hormone therapy (imlunestrant) works compared to standard hormone therapy (exemestane or fulvestrant) and combination therapy (imlunestrant + abemaciclib) in people with ER+/HER2- breast cancer.
 

This trial is treating patients with ER+, HER2- locally advanced or metastatic breast cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Commercial Sponsor

Eli Lilly and Company

Summary

Eligible participants will be randomly allocated to one of three treatment arms. In Arm 1 (Experimental), participants will receive Imlunestrant alone, administered orally. In Arm 2 (Active Comparator), participants will receive the investigator's choice of either Exemestane (administered orally) or Fulvestrant (administered intramuscularly). In Arm 3 (Experimental), participants will receive Imlunestrant plus Abemaciclib, both administered orally.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital, Breast Oncology
Box Hill
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Maroondah Hospital, Maroondah Breast Clinic
Ringwood East
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next